Literature DB >> 9030560

Mutagenesis studies of the human erythropoietin receptor. Establishment of structure-function relationships.

F P Barbone1, S A Middleton, D L Johnson, F J McMahon, J Tullai, R H Gruninger, A E Schilling, L K Jolliffe, L S Mulcahy.   

Abstract

Mutagenesis of the erythropoietin receptor (EPOR) permits analysis of the contribution that individual amino acid residues make to erythropoietin (EPO) binding. We employed both random and site-specific mutagenesis to determine the function of amino acid residues in the extracellular domain (referred to as EPO binding protein, EBP) of the EPOR. Residues were chosen for site-specific alanine substitution based on the results of the random mutagenesis or on their homology to residues that are conserved or have been reported to be involved in ligand binding in other receptors of the cytokine receptor family. Site-specific mutants were expressed in Escherichia coli as soluble EBP and analyzed for EPO binding in several different assay formats. In addition, selected mutant proteins were expressed as full-length EPOR on the surface of COS cells and analyzed for 125I-EPO binding in receptor binding assays. Using these methods, we have identified residues that appear to be involved in EPO binding as well as other residues, most of which are conserved in receptors of the cytokine receptor family, that appear to be necessary for the proper folding and/or stability of the EPOR. We present correlations between these mutagenesis data and the recently solved crystal structure of the EBP with a peptide ligand.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030560     DOI: 10.1074/jbc.272.8.4985

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  3 in total

Review 1.  Drugs for increasing oxygen and their potential use in doping: a review.

Authors:  Aurelie Gaudard; Emmanuelle Varlet-Marie; Francoise Bressolle; Michel Audran
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

2.  Macromolecular docking of a three-body system: the recognition of human growth hormone by its receptor.

Authors:  D K Hendrix; T E Klein; I D Kuntz; T E Klien
Journal:  Protein Sci       Date:  1999-05       Impact factor: 6.725

3.  F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.

Authors:  Norma E Fox; Jihyang Lim; Rose Chen; Amy E Geddis
Journal:  Exp Hematol       Date:  2010-02-24       Impact factor: 3.084

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.